BARDA has provided $24 million in funding to Locus Biosciences as part of a larger $85 million award to advance LBP-EC01, a CRISPR-engineered bacteriophage therapy for resistant E. coli infections.
Phase 2 ELIMINATE trial data indicates that LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, combined with TMP-SMX, is well-tolerated in uUTI patients.
CRISPR-Cas9 gene editing has achieved a significant milestone with FDA approval of Casgevy for sickle cell disease and transfusion-dependent beta thalassemia.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.